Continuous administration of the mTORC1 inhibitor everolimus induces tolerance and decreases autophagy in mice

Potential therapeutic effects of mTOR inhibition in atherosclerosis

(2015) Ammar Kurdi et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The Concise Guide to PHARMACOLOGY 2015/16: Enzymes

(2015) Stephen PH Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

Experimental design and analysis and their reporting: new guidance for publication in BJP

(2015) Michael J Curtis et al.   BRITISH JOURNAL OF PHARMACOLOGY

Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP

(2015) John C McGrath et al.   BRITISH JOURNAL OF PHARMACOLOGY

Autophagy in Vascular Disease

(2015) G. R. Y. De Meyer et al.   CIRCULATION RESEARCH

Cellular and molecular effects of the mTOR inhibitor everolimus

(2015) U. Saran et al.   CLINICAL SCIENCE

mTOR: a pharmacologic target for autophagy regulation

(2015) Young Chul Kim et al.   JOURNAL OF CLINICAL INVESTIGATION

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

(2015) S. M. Guichard et al.   MOLECULAR CANCER THERAPEUTICS

The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

(2015) Christopher Southan et al.   NUCLEIC ACIDS RESEARCH

A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation

(2015) Guang Yang et al.   Cell Reports

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors

(2015) Burhan Hassan et al.   Oncotarget

mTOR inhibition: A promising strategy for stabilization of atherosclerotic plaques

(2014) Wim Martinet et al.   ATHEROSCLEROSIS

Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma

(2014) Siming Li et al.   BMC CANCER

Alternative Mammalian Target of Rapamycin (mTOR) Signal Activation in Sorafenib-resistant Hepatocellular Carcinoma Cells Revealed by Array-based Pathway Profiling

(2014) Mari Masuda et al.   MOLECULAR & CELLULAR PROTEOMICS

HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A

(2014) Eva Juengel et al.   Molecular Cancer

Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer

(2014) Nikhil Wagle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective Inhibition of PI3K/Akt/mTOR Signaling Pathway Regulates Autophagy of Macrophage and Vulnerability of Atherosclerotic Plaque

(2014) Chungang Zhai et al.   PLoS One

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals

(2014) Terence O'Reilly et al.   Translational Oncology

Targeting PI3K/Akt/mTOR Signaling in Cancer

(2014) Camillo Porta et al.   Frontiers in Oncology

Autophagy and human diseases

(2013) Peidu Jiang et al.   CELL RESEARCH

Historical landmarks of autophagy research

(2013) Yoshinori Ohsumi   CELL RESEARCH

Rapamycin Resistance: mTORC1 Substrates Hold Some of the Answers

(2013) Sang-Oh Yoon et al.   CURRENT BIOLOGY

Rapalogs and mTOR inhibitors as anti-aging therapeutics

(2013) Dudley W. Lamming et al.   JOURNAL OF CLINICAL INVESTIGATION

Assessment of Mitochondrial Biogenesis and mTORC1 Signaling During Chronic Rapamycin Feeding in Male and Female Mice

(2013) Joshua C. Drake et al.   JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES

ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase

(2013) Ryan C. Russell et al.   NATURE CELL BIOLOGY

The role of autophagy in neurodegenerative disease

(2013) Ralph A Nixon   NATURE MEDICINE

A Novel Murine Model of Hypertrophic Scarring Using Subcutaneous Infusion of Bleomycin

(2013) Alexander M. Cameron et al.   PLASTIC AND RECONSTRUCTIVE SURGERY

Immunohistochemical analysis of macroautophagy

(2012) Wim Martinet et al.   Autophagy

Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells

(2012) Eva Juengel et al.   CANCER LETTERS

Macrophage Autophagy Plays a Protective Role in Advanced Atherosclerosis

(2012) Xianghai Liao et al.   Cell Metabolism

Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury

(2012) Shunsaku Nakagawa et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Regulation and Function of Uncoordinated-51 Like Kinase Proteins

(2011) Edmond Y. Chan   ANTIOXIDANTS & REDOX SIGNALING

The requirement of uncoordinated 51-like kinase 1 (ULK1) and ULK2 in the regulation of autophagy

(2011) Eun-Ju Lee et al.   Autophagy

The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line

(2011) Igor Tsaur et al.   CANCER LETTERS

Autophagy: for better or for worse

(2011) Ellen Wirawan et al.   CELL RESEARCH

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

(2011) Seth A. Wander et al.   JOURNAL OF CLINICAL INVESTIGATION

AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1

(2011) Joungmok Kim et al.   NATURE CELL BIOLOGY

Rapamycin passes the torch: a new generation of mTOR inhibitors

(2011) Don Benjamin et al.   NATURE REVIEWS DRUG DISCOVERY

Mechanisms of mTOR inhibitor resistance in cancer therapy

(2011) Jennifer S. Carew et al.   Targeted Oncology

Animal research: Reporting in vivo experiments: The ARRIVE guidelines

(2010) Carol Kilkenny et al.   BRITISH JOURNAL OF PHARMACOLOGY

Regulation of cell migration by mTOR is mediated through changes in p27Kip1phosphorylation

(2010) T. Cooper Woods   CELL CYCLE

The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease

(2010) Jonathan H Fox et al.   Molecular Neurodegeneration

RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia

(2009) Roman Crazzolara et al.   Autophagy

Dissecting the role of mTOR: Lessons from mTOR inhibitors

(2009) Ryan J.O. Dowling et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

ULK1·ATG13·FIP200 Complex Mediates mTOR Signaling and Is Essential for Autophagy

(2009) Ian G. Ganley et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

(2009) Carson C. Thoreen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data

(2008) Chiaki Tanaka et al.   JOURNAL OF CLINICAL ONCOLOGY

Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR−/− mice despite severe hypercholesterolemia

(2007) Marc A. Mueller et al.   ATHEROSCLEROSIS